The startup develops boron neutron capture therapy (BNCT) systems and pharmaceuticals specifically targeting tumors and cancers. Their technology enhances treatment efficacy by utilizing neutron irradiation to selectively destroy cancer cells while minimizing damage to surrounding healthy tissue.
Funding
Funding not disclosed
Founders
Product
Problem
Boron neutron capture therapy (BNCT) is a cancer treatment method that requires precise delivery of boron compounds to tumor cells, followed by neutron irradiation. Current BNCT methods may lack the precision needed to target tumors effectively while minimizing damage to healthy tissue. This can limit the efficacy and increase the side effects of the treatment.
Solution
The startup develops integrated BNCT systems and boron-based pharmaceuticals designed to improve the precision and effectiveness of cancer treatment. Their approach focuses on enhancing the selective accumulation of boron compounds within tumor cells. This is followed by neutron irradiation, which induces a nuclear reaction that selectively destroys cancer cells while sparing surrounding healthy tissue. The company aims to optimize the entire BNCT process, from drug delivery to irradiation, to maximize therapeutic outcomes and reduce adverse effects.
Target Audience
The primary target audience includes hospitals, cancer treatment centers, and research institutions specializing in advanced radiation therapies.
Features
- Targeted boron drug delivery systems designed for enhanced tumor accumulation.
- Optimized neutron irradiation protocols to maximize cancer cell destruction.
- Integrated BNCT system combining drug delivery and irradiation technologies.
- Real-time monitoring and control systems for precise treatment delivery.